# Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

> **NCT02162355** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG0634 50 mg
- **DRUG:** GLPG0634 100 mg
- **DRUG:** GLPG0634 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02162355
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162355, "Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02162355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*